122 related articles for article (PubMed ID: 38008032)
1. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.
de Miguel-Perez D; Pickering EM; Malapelle U; Grier W; Pepe F; Pisapia P; Russo G; Pinto JA; Russo A; Troncone G; Culligan MJ; Scilla KA; Mehra R; Mohindra P; Arrieta O; Cardona AF; Del Re M; Sachdeva A; Hirsch FR; Wolf A; Friedberg JS; Rolfo C
Eur J Cancer; 2024 Jan; 196():113457. PubMed ID: 38008032
[TBL] [Abstract][Full Text] [Related]
2. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.
Tsao AS; Harun N; Fujimoto J; Devito V; Lee JJ; Kuhn E; Mehran R; Rice D; Moran C; Hong WK; Shen L; Suraokar M; Wistuba I
Ann Diagn Pathol; 2014 Jun; 18(3):140-5. PubMed ID: 24747001
[TBL] [Abstract][Full Text] [Related]
3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
6. Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.
Opitz I; Bueno R; Lim E; Pass H; Pastorino U; Boeri M; Rocco G;
Eur J Cardiothorac Surg; 2014 Oct; 46(4):602-6. PubMed ID: 24623168
[TBL] [Abstract][Full Text] [Related]
7. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes.
Markowitz P; Patel M; Groisberg R; Aisner J; Jabbour SK; De S; Ganesan S; Malhotra J
Cancer Treat Res Commun; 2020; 25():100232. PubMed ID: 33166854
[TBL] [Abstract][Full Text] [Related]
8. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma.
Paajanen J; Bueno R; De Rienzo A
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362209
[TBL] [Abstract][Full Text] [Related]
9. Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis.
Mosleh B; Schelch K; Mohr T; Klikovits T; Wagner C; Ratzinger L; Dong Y; Sinn K; Ries A; Berger W; Grasl-Kraupp B; Hoetzenecker K; Laszlo V; Dome B; Hegedus B; Jakopovic M; Hoda MA; Grusch M
Thorac Cancer; 2023 Aug; 14(22):2177-2186. PubMed ID: 37340889
[TBL] [Abstract][Full Text] [Related]
10. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
11. Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.
Hama R; Watanabe Y; Shinada K; Yamada Y; Ogata Y; Yoshida Y; Tamura T; Hiraishi T; Oikawa R; Sakurai J; Maehata T; Koizumi H; Itoh F
Tumour Biol; 2012 Dec; 33(6):2031-40. PubMed ID: 22836805
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
Hylebos M; Op de Beeck K; Pauwels P; Zwaenepoel K; van Meerbeeck JP; Van Camp G
Lung Cancer; 2018 Oct; 124():19-22. PubMed ID: 30268460
[TBL] [Abstract][Full Text] [Related]
13. Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study.
Mannarino L; Paracchini L; Pezzuto F; Olteanu GE; Moracci L; Vedovelli L; De Simone I; Bosetti C; Lupi M; Amodeo R; Inglesi A; Callari M; Penpa S; Libener R; Delfanti S; De Angelis A; Muzio A; Zucali PA; Allavena P; Ceresoli GL; Marchini S; Calabrese F; D'Incalci M; Grosso F
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628597
[TBL] [Abstract][Full Text] [Related]
14. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
[TBL] [Abstract][Full Text] [Related]
15. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
[TBL] [Abstract][Full Text] [Related]
16. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
17. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
18. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
[TBL] [Abstract][Full Text] [Related]
19. Identification of actionable mutations in malignant pleural mesothelioma.
Shukuya T; Serizawa M; Watanabe M; Akamatsu H; Abe M; Imai H; Tokito T; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Ohde Y; Nakajima T; Yamamoto N; Koh Y
Lung Cancer; 2014 Oct; 86(1):35-40. PubMed ID: 25174276
[TBL] [Abstract][Full Text] [Related]
20. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations.
Nabeshima K; Hamasaki M; Kinoshita Y; Matsumoto S; Sa-Ngiamwibool P
Pathol Int; 2022 Aug; 72(8):389-401. PubMed ID: 35596704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
